Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 1;2(11):1403-1404.
doi: 10.1001/jamaoncol.2016.2450.

Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy

Yu Zhang  1 , Lieping Chen  2
Affiliations

Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy

Yu Zhang et al. JAMA Oncol. .

Erratum in

  • Error in Figure.
    [No authors listed] [No authors listed] JAMA Oncol. 2016 Nov 1;2(11):1511. doi: 10.1001/jamaoncol.2016.5130. JAMA Oncol. 2016. PMID: 27737439 No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Chen is a consultant and/or advisory board member of and receives consulting fees from MedImmune, NextCure, and Pfizer. Dr Chen also receives patent and/or licensing payments from Bristol-Myers Squibb and Ventana, and currently has sponsored research grants from Boehringer Ingelheim, Pfizer, and NextCure. No other disclosures are reported.

Figures

Figure
Figure. Tumor Immunity in MicroEnvironment (TIME) Classification
B7-H1 indicates B7 homolog 1; IFN, interferon; MHC indicates major histocompatibility complex; PD-1, programmed cell death 1; T1–T4, tumor subtypes; TIL, tumor-infiltrating lymphocyte.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42(4):587–600. - PMC - PubMed
    1. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. - PMC - PubMed
    1. Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 2014;20(4):256–261. - PMC - PubMed
    1. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37. - PMC - PubMed
    1. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391. - PMC - PubMed